Original title: Suspected of fraud! The company issued an announcement that the chairman and a number of vice presidents were detained

Ruiang Gene (688217. SH) actual controller Xiong Hui and four other executives were detained.

The chairman of the board of directors and the three vice presidents were detained

Two of them are siblings

On the evening of October 25, Ruiang Gene announced that the company's actual controller, chairman and general manager, core technical personnel Xiong Hui, actual controller, director and deputy general manager Xiong Jun, deputy general manager He Junyan, deputy general manager Xue Yuwei The compulsory measures have been changed from residential surveillance at a designated location to criminal detention, and the suspected crime has also been changed from illegal business operation to fraud.

According to the announcement, at present, the company has made proper arrangements for related matters, the acting chairman, other senior executives and core technical personnel perform their duties normally, the company's business is carried out normally, and business activities are carried out normally.

According to the Economic Observer, multiple sources said that the matters involved in many of the above-mentioned executives of Ruiang Gene are related to the AstraZeneca insurance fraud case.

On the evening of July 22 this year, Ruiang Gene issued a major announcement saying that it received a notice from the family of Xiong Hui, the actual controller, chairman and general manager, and core technical personnel, the family of Xiong Jun, the actual controller, director and deputy general manager, the family of He Junyan, the deputy general manager, and the family of Xue Yuwei, deputy general manager.

On July 22, Ruiang Gene urgently convened the 25th meeting of the second board of directors to deliberate and pass the "Proposal on Electing Mr. Gao Shangxian to Perform the Duties of the Company's Legal Representative, Chairman and General Manager", and agreed that Gao Shangxian, the actual controller and director of the company, would act as the company's legal representative, chairman and general manager.

According to the prospectus of Ruiang Gene, Xiong Jun is Xiong Hui's younger brother, and Xiong Hui and Gao Shang are husband and wife.

According to the prospectus, Xiong Hui was born in 1972, 52 years old this year, master of internal medicine of Shanghai Jiao Tong University School of Medicine, doctor of microbiology of Fudan University, and postdoctoral fellow of Burnham Institute for Medical Research in United States. Since January 2010, she has successively founded Yuanqi Biotech and Ruiang Co., Ltd., and is responsible for the overall operation of the company.

The net profit in the first half of the year was more than 9 million yuan

According to the official website, Ruiang Gene was established in 2012 and focuses on providing diagnostic products and services with clinical value for tumor precision medicine, such as precise tumor typing, MRD monitoring, and early tumor screening and detection. According to the information on the official website, the history of Ruiang Gene can be traced back to Shanghai Yuanqi Biotechnology, which was established in 2010. In 2012, Ruiang Gene was established, and the company has successively carried out cooperation with well-known companies such as Hengrui, Merck, Agilent, and Illumina, and successfully landed on the Science and Technology Innovation Board in May 2021.

Screenshot of the official website of Ruiang Gene

In June this year, Ruiang Gene said on the investor interactive platform that the company has a number of first or exclusive product certificates in the field of hematological oncology. The company's leukemia 3 fusion gene kit products obtained the Class III medical device certificate in 2012, and it has been the exclusive product in China for up to 6 years, so that the product occupies more than two-thirds of the market share in the initial diagnosis and screening market of leukemia fusion gene detection.

According to the semi-annual report, Ruiang Gene achieved operating income of 135 million yuan in the first half of 2024, a year-on-year increase of 5.66%, and the net profit attributable to the parent company was 9.2218 million yuan, a year-on-year decrease of 43%. Ruiang Gene said that the year-on-year decline in net profit attributable to the parent company was mainly due to two reasons: First, the increase in credit impairment losses of accounts receivable. The company's main customers are medical institutions, affected by the recession in the medical industry, the collection of downstream customers has slowed down, resulting in an increase in accounts receivable aged 1 to 2 years and more than 3 years old, and the company's credit impairment provision for accounts receivable accrued according to aging has increased accordingly. Second, the company's marketing expenses in the company's sales expenses increased.

In the secondary market, the share price of Ruiang Gene fluctuated and fell, and although it rebounded sharply in the past month, it still fell by more than 45% during the year. As of the close of trading on October 25, Ruiang Gene reported 19.57 yuan per share, with the latest market value of 1.1 billion yuan.

This article is synthesized from The Paper, Economic Observer, National Business Daily, etc